anti-tmprss6 monoclonal antibody disc-3405
anti-tmprss6 monoclonal antibody disc-3405: developed by 1 company · 2 clinical trials tracked.
anti-tmprss6 monoclonal antibody disc-3405 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could anti-tmprss6 monoclonal antibody disc-3405 → IRON affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Disc Medicine, Inc. (IRON) Polycythemia Vera (PV); Sickle Cell Disease | Phase 3 |
Clinical Trials (2)
A Phase 1b Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-3405 in Participants With Sickle Cell Disease
Primary endpoint: Safety and tolerability of DISC-3405 administration in participants with SCD
A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DISC-3405 in Participants With Polycythemia Vera (PV)
Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE
Frequently asked questions
Who is developing anti-tmprss6 monoclonal antibody disc-3405?
anti-tmprss6 monoclonal antibody disc-3405 is being developed by Disc Medicine, Inc..
How many clinical trials involve anti-tmprss6 monoclonal antibody disc-3405?
BioSniper tracks 2 clinical trials involving anti-tmprss6 monoclonal antibody disc-3405.